Author

Yaning Wang

Stanford UniversityPrimary ORCID profile (0000-0002-0999-0499 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Yaning WangiD1 paper · Sun Yat-sen University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Dhiraj Suda· 1 shared Dimitris GazgalisiD· 1 shared Felix H. GottliebiD· 1 shared Ilse K. Schaeffner· 1 shared Isidoro TavaresiD· 1 shared Jarrod A. MartoiD· 1 shared Jianwei CheiD· 1 shared Jie JiangiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Dhiraj Suda

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775

Zhengnian Li, Jie Jiang, Yaning Wang, Scott B. Ficarro, Stephen J. Collins, Tyler S. Beyett, Ilse K. Schaeffner, Isidoro Tavares, Felix H. Gottlieb, Dhiraj Suda, Prafulla C. Gokhale, Leah M. Black-Holmes, Dimitris Gazgalis, Michael J. Eck, Pasi Antero Janne, , Tinghu Zhang

This paper develops covalent EGFR inhibitors targeting cysteine 775 and 797, showing improved efficacy and resistance delay in osimertinib-resistant models.

ACS Central Science · Sep 29, 2026Peer-reviewedCancer Biology